文献速递流行病学与生物统计临床试验与 GCP

三联对比双联吸入治疗中度至重度哮喘的结局:系统综述与荟萃分析

Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA · 2021-01-01

高确定性证据显示三联治疗显著降低重度急性发作风险并小幅改善哮喘控制,但生活质量与死亡率无显著差异,且口干和发音障碍风险增加。

要点

  • 三联治疗较双联显著降低重度急性发作风险(RR 0.83,95%CI 0.77-0.90)。
  • 三联治疗对哮喘控制有统计学显著但幅度很小的改善。
  • 三联治疗增加口干和发音障碍风险(RR 1.65,95%CI 1.14-2.38)。

核心结论

  • 在中重度哮喘儿童和成人中,三联治疗较双联治疗显著减少重度急性发作并小幅改善哮喘控制。
  • 两组间哮喘相关生活质量和死亡率无显著差异,三联治疗口干和发音障碍风险增加。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase、CENTRAL、ICTRP、FDA和EMA等数据库至2020年12月8日。

主要发现

  • 重度急性发作:9项试验9932例,三联组22.7% vs 双联组27.4%(RR 0.83,95%CI 0.77-0.90;高确定性)。
  • 哮喘相关生活质量:7项试验5247例,SMD 0.05(95%CI -0.03至0.13),AQLQ均数差 0.05(95%CI -0.03至0.13;中等确定性)。
  • 口干和发音障碍:10项试验7395例,三联组3.0% vs 双联组1.8%(RR 1.65,95%CI 1.14-2.38;高确定性)。

关键数值与推荐

  • 三联治疗降低重度急性发作风险(RR 0.83,95%CI 0.77-0.90),基于9项试验9932例患者的高确定性证据。
  • 哮喘控制改善的ACQ-7均数差为-0.04(95%CI -0.07至-0.01),低于最小重要差异0.5。
  • 生活质量AQLQ均数差0.05(95%CI -0.03至0.13),无显著差异,中等确定性证据。
  • 口干和发音障碍风险增加(RR 1.65,95%CI 1.14-2.38),高确定性证据。

临床怎么用

  • 对于使用ICS+LABA仍未控制的中重度哮喘患者,可考虑加用LAMA组成三联治疗以减少重度急性发作。
  • 加用LAMA前应权衡口干和发音障碍风险,并告知患者相关不良反应。
  • 三联治疗对生活质量和死亡率无显著改善,不应以这些结局作为加用LAMA的主要依据。

局限性

  • 纳入试验使用3种LAMA类型,不同LAMA间效果可能存在差异。
  • 儿童(6-18岁)和成人数据合并分析,儿童特异性结论受限。
  • 生活质量结局为中等确定性证据,且改善幅度低于最小重要差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The benefits and harms of adding long-acting muscarinic antagonists (LAMAs) to inhaled corticosteroids (ICS) and long-acting β2-agonists (LABAs) for moderate to severe asthma remain unclear. OBJECTIVE: To systematically synthesize the outcomes and adverse events associated with triple therapy (ICS, LABA, and LAMA) vs dual therapy (ICS plus LABA) in children and adults with persistent uncontrolled asthma. DATA SOURCES: MEDLINE, Embase, CENTRAL, ICTRP, FDA, and EMA databases from November 2017, to December 8, 2020, without language restriction. STUDY SELECTION: Two investigators independently selected randomized clinical trials (RCTs) comparing triple vs dual therapy in patients with moderate to severe asthma. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted data and assessed risk of bias. Random-effects meta-analyses, including individual patient-level exacerbation data, were used. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach was used to assess certainty (quality) of the evidence. MAIN OUTCOMES AND MEASURES: Severe exacerbations, asthma control (measured using the Asthma Control Questionnaire [ACQ-7], a 7-item list with each item ranging from 0 [totally controlled] to 6 [severely uncontrolled]; minimal important difference, 0.5), quality of life (measured using the Asthma-related Quality of Life [AQLQ] tool; score range, 1 [severely impaired] to 7 [no impairment]; minimal important difference, 0.5), mortality, and adverse events. RESULTS: Twenty RCTs using 3 LAMA types that enrolled 11 894 children and adults (mean age, 52 years [range, 9-71 years]; 57.7% female) were included. High-certainty evidence showed that triple therapy vs dual therapy was significantly associated with a reduction in severe exacerbation risk (9 trials [9932 patients]; 22.7% vs 27.4%; risk ratio, 0.83 [95% CI, 0.77 to 0.90]) and an improvement in asthma control (14 trials [11 230 patients]; standardized mean difference [SMD], -0.06 [95% CI, -0.10 to -0.02]; mean difference in ACQ-7 scale, -0.04 [95% CI, -0.07 to -0.01]). There were no significant differences in asthma-related quality of life (7 trials [5247 patients]; SMD, 0.05 [95% CI, -0.03 to 0.13]; mean difference in AQLQ score, 0.05 [95% CI, -0.03 to 0.13]; moderate-certainty evidence) or mortality (17 trials [11 595 patients]; 0.12% vs 0.12%; risk ratio, 0.96 [95% CI, 0.33 to 2.75]; high-certainty evidence) between dual and triple therapy. Triple therapy was significantly associated with increased dry mouth and dysphonia (10 trials [7395 patients]; 3.0% vs 1.8%; risk ratio, 1.65 [95% CI, 1.14 to 2.38]; high-certainty evidence), but treatment-related and serious adverse events were not significantly different between groups (moderate-certainty evidence). CONCLUSIONS AND RELEVANCE: Among children (aged 6 to 18 years) and adults with moderate to severe asthma, triple therapy, compared with dual therapy, was significantly associated with fewer severe asthma exacerbations and modest improvements in asthma control without significant differences in quality of life or mortality.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Kim LHY, Saleh C, Whalen-Browne A, et al. Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and Meta-analysis. JAMA. 2021. PMID: 34009257. doi:10.1001/jama.2021.7872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。